BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38021795)

  • 21. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis.
    Meijers B; Maas RJ; Sprangers B; Claes K; Poesen R; Bammens B; Naesens M; Deegens JK; Dietrich R; Storr M; Wetzels JF; Evenepoel P; Kuypers D
    Kidney Int; 2014 Mar; 85(3):636-40. PubMed ID: 24402090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soluble Urokinase Receptor Levels in Secondary Focal Segmental Glomerulosclerosis.
    Sun P; Yu L; Huang J; Wang S; Zou W; Yang L; Liu G
    Kidney Dis (Basel); 2019 Oct; 5(4):239-246. PubMed ID: 31768381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
    Chen JS; Chang LC; Wu CZ; Tseng TL; Lin JA; Lin YF; Cheng CW
    J Biomed Sci; 2016 Feb; 23():24. PubMed ID: 26846181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis.
    Harita Y; Ishizuka K; Tanego A; Sugawara N; Chikamoto H; Akioka Y; Tsurumi H; Miura K; Gotoh Y; Tsujita M; Yamamoto T; Horike K; Takeda A; Oka A; Igarashi T; Hattori M
    Pediatr Nephrol; 2014 Sep; 29(9):1553-60. PubMed ID: 24705794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy.
    Alachkar N; Wei C; Arend LJ; Jackson AM; Racusen LC; Fornoni A; Burke G; Rabb H; Kakkad K; Reiser J; Estrella MM
    Transplantation; 2013 Oct; 96(7):649-56. PubMed ID: 23842190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS?
    Schlöndorff D
    Kidney Int; 2014 Mar; 85(3):499-501. PubMed ID: 24583981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates.
    Franco Palacios CR; Lieske JC; Wadei HM; Rule AD; Fervenza FC; Voskoboev N; Garovic VD; Zand L; Stegall MD; Cosio FG; Amer H
    Transplantation; 2013 Aug; 96(4):394-9. PubMed ID: 23736353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Soluble Urokinase-Type Plasminogen Activator Receptor, Changes of 24-Hour Blood Pressure, and Progression of Chronic Kidney Disease.
    Jhee JH; Nam BY; Lee CJ; Park JT; Han SH; Kang SW; Park S; Yoo TH
    J Am Heart Assoc; 2021 Jan; 10(1):e017225. PubMed ID: 33325248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy.
    Wu CZ; Chang LC; Lin YF; Hung YJ; Pei D; Chu NF; Chen JS
    Clin Biochem; 2015 Dec; 48(18):1324-9. PubMed ID: 26162494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urine soluble urokinase-type plasminogen activator receptor levels correlate with proteinuria in Puumala hantavirus infection.
    Outinen TK; Mäkelä S; Huttunen R; Mäenpää N; Libraty D; Vaheri A; Mustonen J; Aittoniemi J
    J Intern Med; 2014 Oct; 276(4):387-95. PubMed ID: 24717117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.
    Harel E; Shoji J; Abraham V; Miller L; Laszik Z; Thurison T; King A; Olshen A; Leung J; Szabo G; Hann B; Høyer-Hansen G; Craik CS; Vincenti F
    Clin Transplant; 2019 Mar; 33(3):e13487. PubMed ID: 30689221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical pattern of nephrotic syndrome in children has no effect on the concentration of soluble urokinase receptor (suPAR) in serum and urine.
    Ochocińska A; Jarmużek W; Janas R
    Pol Merkur Lekarski; 2018 Apr; 44(262):183-187. PubMed ID: 29775445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis.
    Lee JM; Yang JW; Kronbichler A; Eisenhut M; Kim G; Lee KH; Shin JI
    J Immunol Res; 2019; 2019():5679518. PubMed ID: 31089477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Soluble Urokinase Receptor and Chronic Kidney Disease.
    Hayek SS; Sever S; Ko YA; Trachtman H; Awad M; Wadhwani S; Altintas MM; Wei C; Hotton AL; French AL; Sperling LS; Lerakis S; Quyyumi AA; Reiser J
    N Engl J Med; 2015 Nov; 373(20):1916-25. PubMed ID: 26539835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What is the Role of Soluble Urokinase-Type Plasminogen Activator in Renal Disease?
    Saleem MA
    Nephron; 2018; 139(4):334-341. PubMed ID: 29909410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between soluble urokinase-type plasminogen activator receptor and serum biomarkers of endothelial activation in patients with idiopathic nephrotic syndrome.
    Roca N; Jatem E; Martín ML; Muñoz M; Molina M; Martínez C; Segarra A
    Clin Kidney J; 2021 Feb; 14(2):543-549. PubMed ID: 33623677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD.
    Luo S; Coresh J; Tin A; Rebholz CM; Chen TK; Hayek SS; Tracy M; Lipkowitz MS; Appel LJ; Levey AS; Inker LA; Reiser J; Grams ME
    Clin J Am Soc Nephrol; 2018 Jul; 13(7):1013-1021. PubMed ID: 29903900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance.
    Cara-Fuentes G; Wei C; Segarra A; Ishimoto T; Rivard C; Johnson RJ; Reiser J; Garin EH
    Pediatr Nephrol; 2014 Aug; 29(8):1363-71. PubMed ID: 24263531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of saliva and gingival crevicular fluid soluble urokinase plasminogen activator receptor (suPAR), galectin-1, and TNF-α levels in periodontal health and disease.
    Taşdemir İ; Erbak Yılmaz H; Narin F; Sağlam M
    J Periodontal Res; 2020 Oct; 55(5):622-630. PubMed ID: 32166745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble urokinase-type plasminogen activator receptor and incident end-stage renal disease in Chinese patients with chronic kidney disease.
    Lv L; Wang F; Wu L; Wang JW; Cui Z; Hayek SS; Wei C; Reiser J; He K; Zhang L; Chen M; Zhao MH
    Nephrol Dial Transplant; 2020 Mar; 35(3):465-470. PubMed ID: 30124995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.